Efficacité et tolérance à long terme d’une enzymothérapie substitutive la vélaglucérase alfa, chez les patients atteints de la maladie de gaucher de type 1 qui ont switché de l’imiglucérase
Deborah Elstein(Shaare Zedek Medical Center), Ari Zimran(Hebrew University of Jerusalem), Laurie D. Smith(Children's Mercy Hospital), William J. Rhead(Children's Hospital of Wisconsin), A Mehta(The Royal Free Hospital), Pilar Giraldo(Université Paris-Saclay), N. Wang(Lexington VA Health Care System), E. Crombez(Lexington VA Health Care System), Gregory M. Pastores(New York University)
Cited by 0
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders
|New England Journal of Medicine|2007|357
Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation
|Proceedings of the National Academy of Sciences|1998|254
‘Classical’ organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: Long‐term outcome and effects of expanded newborn screening using tandem mass spectrometry
|Journal of Inherited Metabolic Disease|2006|247
Phenylketonuria in adulthood: A collaborative study
|Journal of Inherited Metabolic Disease|2002|215